CXCR4 and neoplasm: During the last decade, great interest has particularly been paid to the AMD3465-derived molecule AMD3100 (plerixafor, Mozobil®, Figure 5a), a bicyclam that selectively and reversibly binds within the CXCR4 to disrupt tumor-stroma interactions and that mobilizes hematopoietic stem and progenitor cells to the peripheral blood compartment [139].